With maturity comes confidence: EBCTCG tamoxifen update.

摘要

In The Lancet, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) have updated their meta-analyses of long-term outcomes in 21457 women with early-stage breast cancer, in 20 randomised trials of about 5 years of adjuvant tamoxifen versus observation or placebo. The EBCTCG should be commended for their commitment to update and investigate a collaborative database with such breadth and maturity (median follow-up is now 13 years). They showed that allocation to about 5 years of tamoxifen reduces the recurrence rate substantially throughout the first decade (rate ratio [RR] 0-53 [SE 003] in years 0-4 and 0-68 [006] in years 5-9), with no subsequent loss of the gains made during the first decade.